Abstract

Research Article

Mechanism of Small Molecule Inhibitors of Phagocytosis

Melika Loriamini, Melissa M Lewis-Bakker, Beth Binnington, Lakshmi P Kotra and Donald R Branch*

Published: 03 July, 2023 | Volume 7 - Issue 1 | Pages: 011-014

Immune cytopenias occur when the body produces antibodies that target specific hematopoietic cells, inducing extravascular antibody-mediated phagocytosis by monocyte-macrophages in the spleen and/or liver through activation of Fcγ Receptors (FcγRs). Immune cytopenias include Immune Thrombocytopenia (ITP), Autoimmune Hemolytic Anemia (AIHA), Hemolytic Transfusion Reactions (HTR), Hemolytic Disease of the Fetus and Newborn (HDFN), and Autoimmune Neutropenia (AIN). Thus, novel therapeutics that inhibit phagocytosis would be useful, especially for short-term use while other therapies are being evaluated. In our earlier studies, we successfully identified two small-molecule drugs able to inhibit in vitro phagocytosis with a low IC50 concentration and negligible toxicity. These drugs, known as KB-151 and KB-208, have the potential to be utilized as lead compounds for further studies, once their mechanism of action is more clearly understood. In this regard, we have developed preliminary results that suggest that these small molecules may bind to the Fc receptors on monocyte macrophages and block the subsequent attachment of antibody-opsonized red blood cells to prevent phagocytosis.

Read Full Article HTML DOI: 10.29328/journal.jhcr.1001022 Cite this Article Read Full Article PDF

References

  1. Gilliland BC, Evans RS. The immune cytopenias. Postgrad Med. 1973 Nov;54(5):195-203. doi: 10.1080/00325481.1973.11713621. PMID: 4583297.
  2. Petz LD, Garratty G. Immune Hemolytic Anemias, 2nd; Petz LD, Garratty G, Eds, Churchill Livingstone: Philadelphia. PA, USA. 2004.
  3. Connell NT, Berliner N. Fostamatinib for the treatment of chronic immune thrombocytopenia. Blood. 2019 May 9;133(19):2027-2030. doi: 10.1182/blood-2018-11-852491. Epub 2019 Feb 25. PMID: 30803989.
  4. Zuercher AW, Spirig R, Baz Morelli A, Rowe T, Käsermann F. Next-generation Fc receptor-targeting biologics for autoimmune diseases. Autoimmun Rev. 2019 Oct;18(10):102366. doi: 10.1016/j.autrev.2019.102366. Epub 2019 Aug 9. PMID: 31404703.
  5. Loriamini M, Lewis-Bakker MM, Frias Boligan K, Wang S, Holton MB, Kotra LP, Branch DR. Small Molecule Drugs That Inhibit Phagocytosis. Molecules. 2023 Jan 12;28(2):757. doi: 10.3390/molecules28020757. PMID: 36677815; PMCID: PMC9867408.
  6. Purohit MK, Scovell I, Neschadim A, Katsman Y, Branch DR, Kotra LP. Disulfide linked pyrazole derivatives inhibit phagocytosis of opsonized blood cells. Bioorg Med Chem Lett. 2013 Apr 15;23(8):2324-7. doi: 10.1016/j.bmcl.2013.02.064. Epub 2013 Feb 26. PMID: 23489619.
  7. Purohit MK, Chakka SK, Scovell I, Neschadim A, Bello AM, Salum N, Katsman Y, Bareau MC, Branch DR, Kotra LP. Structure-activity relationships of pyrazole derivatives as potential therapeutics for immune thrombocytopenias. Bioorg Med Chem. 2014 May 1;22(9):2739-52. doi: 10.1016/j.bmc.2014.03.016. Epub 2014 Mar 19. PMID: 24685704.
  8. Tong TN, Burke-Murphy E, Sakac D, Pendergrast J, Cserti-Gazdewich C, Laroche V, Branch DR. Optimal conditions for the performance of a monocyte monolayer assay. Transfusion. 2016 Nov;56(11):2680-2690. doi: 10.1111/trf.13766. Epub 2016 Aug 21. PMID: 27546234.
  9. Tong TN, Cen S, Branch DR. The Monocyte Monolayer Assay: Past, Present and Future. Transfus Med Rev. 2019 Jan;33(1):24-28. doi: 10.1016/j.tmrv.2018.07.004. Epub 2018 Aug 8. PMID: 30139679.
  10. Rampersad GC, Suck G, Sakac D, Fahim S, Foo A, Denomme GA, Langler RF, Branch DR. Chemical compounds that target thiol-disulfide groups on mononuclear phagocytes inhibit immune mediated phagocytosis of red blood cells. Transfusion. 2005 Mar;45(3):384-93. doi: 10.1111/j.1537-2995.2005.04241.x. PMID: 15752156.
  11. Ghanima W, Godeau B, Cines DB, Bussel JB. How I treat immune thrombocytopenia: the choice between splenectomy or a medical therapy as a second-line treatment. Blood. 2012 Aug 2;120(5):960-9. doi: 10.1182/blood-2011-12-309153. Epub 2012 Jun 26. PMID: 22740443.
  12. Thompson JC, Klima J, Despotovic JM, O'Brien SH. Anti-D immunoglobulin therapy for pediatric ITP: before and after the FDA's black box warning. Pediatr Blood Cancer. 2013 Nov;60(11):E149-51. doi: 10.1002/pbc.24633. Epub 2013 Jun 27. PMID: 23813881.
  13. Long M, Kalish LA, Neufeld EJ, Grace RF. Trends in anti-D immune globulin for childhood immune thrombocytopenia: usage, response rates, and adverse effects. Am J Hematol. 2012 Mar;87(3):315-7. doi: 10.1002/ajh.22261. Epub 2011 Dec 21. PMID: 22190130; PMCID: PMC3767405.
  14. Almizraq RJ, Branch DR. Efficacy and mechanism of intravenous immunoglobulin treatment for immune thrombocytopenia in adults. Ann Blood 2021; 6:2.
  15. Braselmann S, Taylor V, Zhao H, Wang S, Sylvain C, Baluom M, Qu K, Herlaar E, Lau A, Young C, Wong BR, Lovell S, Sun T, Park G, Argade A, Jurcevic S, Pine P, Singh R, Grossbard EB, Payan DG, Masuda ES. R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation. J Pharmacol Exp Ther. 2006 Dec;319(3):998-1008. doi: 10.1124/jpet.106.109058. Epub 2006 Aug 31. Erratum in: J Pharmacol Exp Ther. 2013 May;345(2):326. PMID: 16946104.
  16. McKeage K, Lyseng-Williamson KA. Fostamatinib in chronic immune thrombocytopenia: a profile of its use in the USA. Drugs Ther Perspect. 2018;34(10):451-456. doi: 10.1007/s40267-018-0551-x. Epub 2018 Aug 29. Erratum in: Drugs Ther Perspect. 2018;34(12):594. PMID: 30459507; PMCID: PMC6223701.
  17. Cheloff AZ, Al-Samkari H. Avatrombopag for the treatment of immune thrombocytopenia and thrombocytopenia of chronic liver disease. J Blood Med. 2019 Sep 5;10:313-321. doi: 10.2147/JBM.S191790. PMID: 31565009; PMCID: PMC6733339.
  18. Cohn CS, Bussel JB. Romiplostim: a second-generation thrombopoietin agonist. Drugs Today (Barc). 2009 Mar;45(3):175-88. doi: 10.1358/dot.2009.45.3.1343793. PMID: 19436840.

Figures:

Similar Articles

Recently Viewed

Read More

Most Viewed

Read More

Help ?